.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

ePoster
P022

Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial

Appointment

Date: 06/12/2023

Time: 19:40 – 19:45

Talk time: 3 Min.

Discussion time: 2 Min.

Location / Stream:

Headache theatre

Poster

Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial

Session

ePoster 02

Topic

New developments in prophylactic medications and acute medications